18:20 , Aug 31, 2018 |  BC Week In Review  |  Company News

Novo acquires Ziylo in quest for glucose-sensitive insulin

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) acquired Ziylo Ltd. (Bristol, U.K.), giving the pharma a platform that could help it develop a glucose-responsive insulin. Novo has identified glucose-sensitive insulin as an important innovative area for...
22:08 , Aug 23, 2018 |  BC Innovations  |  Product R&D

Sweet switch

Novo Nordisk A/S is betting Ziylo Ltd.’s glucose-responsive compounds can unlock development of smart insulins that are a step up for diabetes therapy. Unlike the competitors, which mostly act when blood glucose is high, Ziylo’s...
15:38 , Aug 17, 2018 |  BC Extra  |  Company News

Novo acquires Ziylo in quest for glucose-sensitive insulin

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) acquired Ziylo Ltd. (Bristol, U.K.), giving the pharma a platform that could help it develop a glucose-responsive insulin. Novo has identified glucose-sensitive insulin as an important innovative area for...